ARTICLE | Clinical News
Dextenza sustained-release dexamethasone: Phase III data
June 27, 2016 7:00 AM UTC
Top-line data from a double-blind, U.S. Phase III trial in 86 patients with allergic conjunctivitis showed that 0.4 mg Dextenza intracanalicular depot given 48-72 hours after first exposure to allerge...